NCT07202663View on ClinicalTrials.gov

Study of BB-025, Alone and After BB-031, in Healthy Volunteers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
PharmacodynamicsPharmacokineticsHealthy Volunteers
Interventions
DRUG

BB-025

Reversal agent for BB-031

DRUG

BB-031

RNA aptamer

Trial Locations (1)

Unknown

Scintia Clinical Research Ltd, Randwick

Sponsors
All Listed Sponsors
lead

Basking Biosciences, Inc.

INDUSTRY